Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Similar documents
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

DENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma

Measure #408: Opioid Therapy Follow-up Evaluation National Quality Strategy Domain: Effective Clinical Care

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

Quality ID #406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Quality ID #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care

Quality ID# 406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

College of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS

Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care

Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

DESCRIPTION: Percentage of women years of age who had a mammogram to screen for breast cancer

Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period

This is a two-part measure which is paired with Measure #154: Falls: Risk Assessment.

DESCRIPTION: Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient

Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

Quality ID #293: Parkinson s Disease: Rehabilitative Therapy Options National Quality Strategy Domain: Communication and Care Coordination

Quality ID #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination

Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

Quality ID #351: Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation National Quality Strategy Domain: Patient Safety

DESCRIPTION: Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

Quality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety

Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Intermediate Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged Years of Age National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Measure #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety

Measure #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Measure #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Transcription:

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of esophageal biopsy reports that document the presence of Barrett s mucosa that also include a statement about dysplasia INSTRUCTIONS: This measure is to be submitted each time a patient s surgical pathology report demonstrates Barrett s Esophagus; however, only one quality-data code (QDC) per date of service for a patient is required. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission: The listed denominator criteria is used to identify the intended patient population. The numerator quality-data codes included in this specification are used to submit the quality actions allowed by the measure. All measure-specific coding should be submitted on the claim(s) representing the eligible encounter. DENOMINATOR: All surgical pathology biopsy reports for Barrett s Esophagus Denominator Criteria (Eligible Cases): Diagnosis for Barrett s esophagus (ICD-10-CM): K22.70, K22.710, K22.711, K22.719 AND Patient procedure during the performance period (CPT): 88305 NUMERATOR: Esophageal biopsy report documents the presence of Barrett s mucosa and includes a statement about dysplasia NUMERATOR NOTE: Submit quality data codes once per patient for each date-of-service. OR OR Numerator Quality-Data Coding Options: If Patient is not Eligible for this Measure because the Specimen is not of Esophageal Origin Report: Denominator Exclusion: G8797: Specimen site other than anatomic location of esophagus Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite and if present, contains appropriate grading) Performance Met: CPT II 3126F: Esophageal biopsy reports with the histological finding of Barrett s mucosa that contains a statement about dysplasia (present, absent, or indefinite and if present, contains appropriate grading) Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite) not Performed for Medical Reasons Append a modifier (1P) to Category II code 3126F to submit documented circumstances that appropriately exclude patients from the denominator Page 1 of 5

OR Denominator Exception: 3126F with 1P: Documentation of medical reason(s) for not submitting the histological finding of Barrett s mucosa (e.g., malignant neoplasm or absence of intestinal metaplasia) Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that does not Contain a Statement about Dysplasia (present, absent, or indefinite), Reason not Otherwise Specified Append a submit modifier (8P) to CPT Category II code 3126F to submit circumstances when the action described in the numerator is not performed and the reason is not otherwise specified Performance Not Met: 3126F with 8P: Pathology report with the histological finding of Barrett s mucosa that does not contain a statement about dysplasia (present, absent, or indefinite, and if present, contains appropriate grading), reason not otherwise specified RATIONALE: Endoscopy is the technique of choice used to identify suspected Barrett s esophagus and to diagnose complications of GERD. Biopsy must be added to confirm the presence of Barrett s epithelium and to evaluate for dysplasia (ACG, 2005). There is a rapidly rising incidence of adenocarcinoma of the esophagus in the United States. A diagnosis of Barrett s esophagus increases a patient s risk for esophageal adenocarcinoma by 30 to 125 times that of people without Barrett s esophagus (although this risk is still small 0.4% to 0.5% per year). Esophageal adenocarcinoma is often not curable, partly because the disease is frequently discovered at a late stage and because treatments are not effective. A diagnosis of Barrett s esophagus could allow for appropriate screening of at risk patients as recommended by the American College of Gastroenterology. Standard endoscopy with biopsy currently is the most reliable means of establishing a diagnosis of Barrett s esophagus. The definitive diagnosis of Barrett s esophagus requires a pathologist s review of an esophageal biopsy. Dysplasia is the first step in the neoplastic process, and information about dysplasia is crucial for clinical decision- making directing therapy. The presence and grade of dysplasia cannot be determined by routine endoscopy, and pathologist s review of a biopsy is essential for recognition of dysplasia. Endoscopic surveillance detects curable neoplasia in patients with Barrett s esophagus. CLINICAL RECOMMENDATION STATEMENTS: The diagnosis of Barrett s esophagus requires systematic biopsy of the abnormal-appearing esophageal mucosa to document intestinal metaplasia and to detect dysplasia. COPYRIGHT: THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. 2007 and 2012 College of American Pathologists. All Rights Reserved Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The College of American Pathologists disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT ) or other coding contained in the specifications. CPT contained in the Measures specifications is copyright 2004-2017 American Medical Association. Page 2 of 5

Page 3 of 5

2018 Claims Flow for Quality ID #249: NQF #1854: Barrett s Esophagus Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for claims data submission. 1. Start with Denominator 2. Check Patient Diagnosis: a. If Diagnosis of Barrett s Esophagus as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Diagnosis of Barrett s Esophagus as Listed in the Denominator equals Yes, proceed to check Procedure Performed. 3. Check Procedure Performed: a. If Procedure as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Procedure as Listed in the Denominator equals Yes, include in the Eligible Population. 4. Denominator Population: a. Denominator population is all Eligible Procedures in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 procedures in the Sample Calculation. 5. Start Numerator 6. Specimen Site other than Anatomic Location of Esophagus: a. If Specimen Site other than Anatomic Location of Esophagus equals Yes, include in Data Completeness Met and Denominator Exclusion. b. Data Completeness Met and Denominator Exclusion letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x equals 0 procedures in the Sample Calculation. c. If Specimen Site other than Anatomic Location of Esophagus equals No, proceed to Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite and if Present Contains Appropriate Grading). 7. Check Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite and if Present Contains Appropriate Grading): a. If Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite and if Present Contains Appropriate Grading) equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 procedures in Sample Calculation. Page 4 of 5

c. If Esophageal Biopsy Reports with the Histological Finding of Barrett s Mucosa that Contains a Statement about Dysplasia (present, absent, or indefinite and if Present Contains Appropriate Grading) equals No, proceed to Documentation of Medical Reason(s) for Not Submitting the Histological Finding of Barrett s Mucosa. 8. Check Documentation of Medical Reason(s) for Not Submitting the Histological Finding of Barrett s Mucosa: a. If Documentation of Medical Reason(s) for Not Submitting the Histological Finding of Barrett s Mucosa equals Yes, include in Data Completeness Met and Denominator Exception. b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 procedures in the Sample Calculation. c. If Documentation of Medical Reason(s) for Not Submitting the Histological Finding of Barrett s Mucosa equals No, proceed to Pathology Report with the Histological Finding of Barrett s Mucosa that does not Contain a Statement about Dysplasia (present, absent, or indefinite, and if present, contains appropriate grading), Reason Not Specified. 9. Check Pathology Report with the Histological Finding of Barrett s Mucosa that does not Contain a Statement Specified: a. If Pathology Report with the Histological Finding of Barrett s Mucosa that does not Contain a Statement Specified equals Yes, include in the Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 procedures in the Sample Calculation. c. If Pathology Report with the Histological Finding of Barrett s Mucosa that does not Contain a Statement Specified equals No, proceed to Data Completeness Not Met. 10. Check Data Completeness Not Met a. If Data Completeness Not Met equals No, Quality Data Code not submitted. 10 procedures have been subtracted from Data Completeness Numerator in the Sample Calculation. Page 5 of 5